Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

AZN

Astrazeneca plc

May 22 • 04:00PM ET

187.03

-2.72 -1.43 %

Healthcare • Drug Manufacturers - General • United Kingdom • Mega • NYSE

Peers: MRK ABBV JNJ BMY PFE LLY NVO SNY GSK AMGN

| Held by: PVAL AVDE DIHP DFIC PPH PBPH FVD DFAX BDYN JDVL

Scroll to Statements

Index	-	P/E	28.10	EPS (ttm)	6.66	Insider Own	4.82%	Shs Outstand	1.55B	Perf Week	3.00%
Market Cap	290.06B	Forward P/E	16.06	EPS next Y	11.65	Insider Trans	-0.02%	Shs Float	1.48B	Perf Month	-2.74%
Enterprise Value	316.35B	PEG	1.31	EPS next Q	2.50	Inst Own	61.32%	Short Float	0.12%	Perf Quarter	-8.74%
Income	10.39B	P/S	4.80	EPS this Y	12.25%	Inst Trans	-12.07%	Short Ratio	0.95	Perf Half Y	4.01%
Sales	60.44B	P/B	6.13	EPS next Y	13.28%	ROA	9.43%	Short Interest	1.83M	Perf YTD	6.57%
Book/sh	30.52	P/C	37.79	EPS next 5Y	12.30%	ROE	23.51%	52W High	212.71 -12.07%	Perf Year	32.53%
Cash/sh	4.95	P/FCF	24.81	EPS past 3/5Y	45.90% 22.05%	ROIC	14.17%	52W Low	134.90 38.64%	Perf 3Y	26.46%
Dividend Est.	3.35 (1.79%)	EV/EBITDA	15.93	Sales past 3/5Y	9.82% 16.31%	Gross Margin	74.32%	Volatility	1.73% 1.66%	Perf 5Y	59.85%
Dividend TTM	3.20 (1.71%)	EV/Sales	5.23	EPS Y/Y TTM	33.66%	Oper. Margin	23.23%	ATR (14)	3.89	Perf 10Y	232.50%
Dividend Ex-Date	Feb 20, 2026	Quick Ratio	0.71	Sales Y/Y TTM	9.93%	Profit Margin	17.19%	RSI (14)	48.49	Recom	1.61
Dividend Gr. 3/5Y	1.78% 3.25%	Current Ratio	0.91	EPS Q/Q	5.63%	SMA20	1.10%	Beta	0.30	Target Price	223.94
Payout	47.19%	Debt/Eq	0.72	Sales Q/Q	12.51%	SMA50	-2.20%	Rel Volume	1.10	Prev Close	189.75
Employees	96100	LT Debt/Eq	0.55	Earnings	Apr 29 BMO	SMA200	4.83%	Avg Volume	1.93M	Price	187.03
IPO	Oct 17, 2003	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.34% 2.38%	Trades		Volume	2,120,772	Change	-1.43%

May-21-26 05:38AM	Lillys triple-acting obesity drug hits goal in Phase 3 trial (BioPharma Dive)
May-20-26 05:06AM	Big Pharma is gambling on specialized R&D. Will it pay off? (Pharma Voice)
May-18-26 09:02AM	AstraZeneca Wins FDA Approval for $5 Billion Blood Pressure Drug (GuruFocus.com)
08:04AM	FDA approves AstraZenecas new kind of hypertension drug (BioPharma Dive)
07:00AM	BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension (Business Wire)
02:53AM	Loading…
02:53AM	AstraZeneca wins US approval for first-in-class blood pressure drug and expands cancer treatment Enhertu (Proactive)
02:15AM	FTSE 100 Live: Stocks spike on reports of progress in Iran-US negotiations (Proactive)
May-15-26 07:36AM	Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers (BioPharma Dive)
May-14-26 07:00AM	Perioperative IMFINZI (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial (Business Wire)
May-13-26 07:28AM	UAE approves AstraZeneca's Baxfendy for hypertension (Pharmaceutical Business Review)
05:00AM	Why the FDAs push for real-time clinical trials could favor Big Pharma (Pharma Voice)
02:17AM	FTSE 100 Live: London stocks in red, Babcock gains offset by bond worries over Starmer (Proactive)
May-11-26 06:00PM	PRIMECAP Management's Strategic Moves: AstraZeneca PLC Exits with a -2.57% Impact (GuruFocus.com)
May-07-26 11:34AM	Why This Income Pro Likes Banks, Chip-Equipment Companies, and More (Barrons.com)
May-06-26 07:07PM	Ken Fisher's Strategic Moves: AstraZeneca PLC Leads the Portfolio Additions (GuruFocus.com)
08:28AM	Loading…
May-01-26 08:28AM	Summits self-inflicted stumble; Esperions take-private deal (BioPharma Dive)
08:10AM	AstraZeneca stock sinks after FDA advisers vote against its breast cancer drug (Quartz)
08:01AM	AstraZeneca stock falls after FDA panel rejects breast cancer drug (Quartz)
05:48AM	AstraZeneca shares drop after US regulators vote against breast cancer drug (Reuters Videos)
04:46AM	AstraZeneca falls as FDA advisers reject breast cancer drug use (Proactive)
04:06AM	AstraZeneca slips after FDA panel rejects breast cancer drug camizestrant (Investing.com)
Apr-30-26 09:42PM	TRUQAP (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer (Business Wire)
08:32AM	Citi raises AstraZeneca earnings forecast and maintains 'buy' rating ahead of second-half pipeline catalysts (Proactive)
Apr-29-26 07:00PM	Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca (PR Newswire)
12:12PM	AstraZeneca to invest £300m in Britain as Starmer pays more for drugs (The Telegraph)
11:12AM	AstraZeneca beats Q1 estimates, CEO says drug pipeline is 'delivering' (Yahoo Finance Video)
08:06AM	Astrazeneca tops expectations in the first quarter on strong cancer drug sales (Associated Press)
07:58AM	AstraZeneca Q1 2026 earnings beat on cancer drug sales (Quartz)
07:21AM	FDA tests out real-time clinical trials; AbbVie closes in on a KRAS biotech (BioPharma Dive)
06:09AM	American industry is winning: White House touts factory boom how investors can ride the reshoring wave (Moneywise)
03:09AM	Loading…
03:09AM	AstraZeneca tops Q1 forecasts on strong cancer, rare-disease drug demand (Investing.com)
02:36AM	Astrazeneca: Q1 Earnings Snapshot (Associated Press)
02:16AM	FTSE 100 Live: Stocks sink as oil pushes 4yr highs, AstraZeneca, GSK, Lloyds report (Proactive)
02:16AM	FTSE 100 Live: Sluggish start as AstraZeneca, Haleon results disappoint (Proactive)
02:03AM	AstraZeneca sticks to its guns after strong first-quarter revenue growth (Proactive)
Apr-28-26 03:00PM	FDA is launching real-time monitoring of drug trials, with AstraZeneca and Amgen as first test cases (Quartz)
09:15AM	Earnings To Watch: AstraZeneca PLC (LSE:AZN) Reports Q1 2026 Result (GuruFocus.com)
05:55AM	FDA approves AstraZeneca's Saphnelo for SLE (Pharmaceutical Business Review)
02:06AM	FTSE 100 Live: Barclays leads blue-chips lower after results, oil hits $110 a barrel (Proactive)
Apr-27-26 08:04AM	Citi sees Daiichi supply review as immaterial for AstraZeneca (Proactive)
07:00AM	SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus (Business Wire)
Apr-21-26 01:01PM	T Rowe Price Equity Income Fund's Strategic Moves: AstraZeneca PLC Takes Center Stage (GuruFocus.com)
08:03AM	AstraZeneca's tozorakimab treble puts $5bn sales ceiling in sight, says Citi (Proactive)
03:16AM	AstraZeneca's Ultomiris hits primary endpoint in rare kidney disease trial (Proactive)
02:16AM	FTSE 100 Live: Stocks open flat as market awaits signals on Iran-US talks (Proactive)
02:16AM	FTSE 100 Live: London stocks mixed as bond markets eye Starmer pressure (Proactive)
Apr-20-26 07:00AM	Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD (Business Wire)
Apr-17-26 06:44AM	The innovators working to make in vivo cell therapy a reality (Pharmaceutical Technology)
Apr-15-26 03:17AM	FTSE 100 Live: Shares mixed as Iran talks awaited, Ceres and Rank jump (Proactive)
Apr-13-26 12:48PM	GSK Plans Five Late-Stage Cancer Trials As Shares Rise Nearly 50% (GuruFocus.com)
Apr-10-26 05:01PM	Parnassus Value Equity Fund's Strategic Moves: AstraZeneca PLC Takes Center Stage (GuruFocus.com)
10:31AM	AstraZeneca faces China headwinds and key drug launches as two banks back 20% upside (Proactive)
Apr-08-26 08:09AM	Virginia governor signs 4 laws establishing manufacturing grant programs (Manufacturing Dive)
Apr-07-26 07:15AM	FTSE 100 Live: Defence and gold miners drag as Trump's new Iran deadline awaited (Proactive)
07:00AM	AstraZeneca's liver cancer breakthrough puts Imfinzi on course to become a super-blockbuster drug (Proactive)
Apr-01-26 09:15AM	US bank sees AstraZeneca HPP drug data as supportive of $2.6bn forecast with upside to $4.4bn despite mixed trial results (Proactive)
Mar-31-26 03:45PM	$2 Billion Bayer Verdict: What the Roundup Decision Means for MAHA (Exec Edge)
09:04AM	Lilly's $2 Billion AI Deal Raises Stakes (GuruFocus.com)
Mar-30-26 10:15AM	Tozorakimab trial success hands AstraZeneca a crucial edge in the race to crack COPD's hardest-to-treat patients (Proactive)
05:23AM	FTSE 100 Live: Blue-chip index climbs as oil price rises but bonds ease (Proactive)
02:03AM	Connecting Excellence Group appoints chief performance and growth officer (Proactive)
Mar-27-26 07:00AM	Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD (Business Wire)
04:41AM	AstraZeneca shares rise to top of FTSE 100 as COPD drug clears two pivotal trials (Proactive)
Mar-26-26 03:00PM	Innate Pharma SA (IPHA) Full Year 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Mar-24-26 10:30AM	Advancements in Novel Immunotherapeutics in The Oncology Battle (Newsfile)
Mar-19-26 11:39AM	Long-only funds are buying non-US stocks, BofA says (Investing.com)
03:22AM	AstraZeneca to boost cell therapy capabilities with new China investment (BioPharma Dive)
Mar-18-26 02:29PM	Analysis-TrumpRx lists many medicines at prices higher than paid in UK (Reuters)
Mar-16-26 07:02AM	Building materials giant abandons London stock market (The Telegraph)
07:02AM	£50bn construction giant abandons London stock market (The Telegraph)
Mar-12-26 02:55PM	Abivax Pushes Back On Takeover Rumors (Moby)
03:33AM	Poolbeg Pharma adds CAR-T therapy expert to scientific advisory board (Proactive)
Mar-10-26 08:30AM	AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer (Business Wire)
Mar-09-26 09:35AM	Will Weak Gardasil Sales Continue to Weigh on MRK's Top Line in 2026? (Zacks)
07:00AM	ENHERTU (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer (Business Wire)
02:30AM	ENHERTU Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer (Business Wire)
Mar-06-26 06:37PM	Analyst Report: AstraZeneca PLC (Morningstar Research)
09:50AM	Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term (Zacks)
08:21AM	Will Linzess Continue to Aid IRWD's Top Line in 2026 After a Soft Q4? (Zacks)
07:17AM	Jefferies raises AstraZeneca target to 18,000p as analysts flip view on delayed cancer trial (Proactive)
05:22AM	The Zacks Analyst Blog Highlights Exxon Mobil, Palantir, AstraZeneca, Gencor Industries and Hour Loop (Zacks)
Mar-05-26 04:31PM	Top Analyst Reports for Exxon Mobil, Palantir & AstraZeneca (Zacks)
09:40AM	Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term (Zacks)
08:45AM	Can Pfizer Reignite Growth Amid COVID Declines and Patent Expirations? (Zacks)
06:00AM	Royalty Rift: Alexion Cuts Off US Royalty Payments To Xencor (Benzinga)
Mar-03-26 08:03PM	Compugen Ltd (CGEN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
10:05AM	Merck's Keytruda Drives its 2025 Revenue Surge: What's Ahead? (Zacks)
Mar-02-26 06:51PM	Salesforce CEO touts company resilience amid software slump (TheStreet)
12:31PM	Compugen Ltd. Q4 2025 Earnings Call Summary (Moby)
08:23AM	As Investors Flee U.S. Equities, This Global ETF Is Outperforming (MarketBeat)
Feb-26-26 10:04PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
10:40AM	IRWD Q4 Earnings and Revenues Fall Shy of Estimates, Stock Tanks (Zacks)
09:18AM	Ionis Q4 Earnings & Sales Beat, Stock Down on Soft 2026 Outlook (Zacks)
09:02AM	AstraZeneca has 'sector leading replacement power' to cope with 2030 patent cliff (Proactive)
08:30AM	Novavax, Inc. Q4 2025 Earnings Call Summary (Moby)
Feb-25-26 08:49AM	Can J&J Sustain Its Double-Digit Oncology Growth Streak? (Zacks)
05:05AM	GSK to Buy 35Pharma for $950 Million (The Wall Street Journal)
01:07AM	Tempus AI Q4 Earnings Call Highlights (MarketBeat)
Feb-24-26 06:01AM	Health Care Roundup: Market Talk (The Wall Street Journal)
Feb-23-26 06:35AM	AstraZeneca's Calquence plus venetoclax gains approval in US to treat CLL (Pharmaceutical Business Review)

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

M.B.A.Mr. Pascal Claude Roland Soriot D.V.M.

CFO & Executive DirectorDr. Aradhana Sarin M.D.

EVP of Global opt. & ITMs. Pam P. Cheng

Head of Investor RelationsMr. Joris Silon

CHROMr. Jeffrey Pott J.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sharma Mani	See Remarks	May 20 '26	Sale	185.78	11,893	2,209,482	19,262	May 22 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AZN

Astrazeneca plc

Upgrade your Finviz experience